IPO Opportunity Mobia Medical, Inc. recently completed an IPO raising about $150M and is a commercial-stage medical device company with FDA-approved Vivistim system for chronic ischemic stroke. This signals increased capital availability and a readiness to scale sales, distribution, and payer engagement for their neurostimulation therapy.

Expansion Readiness With a public listing and rapid revenue growth despite losses, Mobia Medical appears positioned for market expansion. Sales teams should target hospital systems, rehabilitation centers, and large stroke clinics to accelerate adoption of Vivistim Paired VNS Therapy across broader geographies.

Clinical Differentiator Vivistim Paired VNS Therapy is FDA-approved and designed to improve upper limb function in chronic stroke survivors. Sales opportunities exist in expanding indications within neurorehabilitation, pursuing payer coverage dialogues, and upselling to centers seeking breakthrough neuroplasticity therapies.

Financial Targeting Current revenue range ($25M–$50M) and raised funding ($65M) indicate growth potential but ongoing profitability concerns. Focused BD efforts should emphasize high-value contracts, favorable reimbursement pathways, and case-based ROI analyses to convert pilots into scaled deployments.

Competitive Positioning As a mid-sized medtech with a distinctive implantable solution, Mobia Medical competes with larger neurostimulation players. Opportunities include targeting mid-to-large healthcare networks and leveraging success stories with comparable firms to demonstrate cost-effectiveness and clinical outcomes to procurement teams.